CORDIS
EU research results

CORDIS

English EN

Big Data and models for personalized Head and Neck Cancer Decision support

Objective

"Cancers of the Head and Neck Region (HNC) are the 6th more deadly cancers worldwide: in Europe ~150.000 new cases are detected and ~70.000 patients die every year. The main reasons for high mortality are the fact that the majority of cases are diagnosed in advanced Stage and the intrinsic heterogeneity of such tumors. At present the only adopted treatment decision method is based on TNM (Tumor-lymph-Nodes-Metastasis) prognostic system, that considers only a few risk factors such as smoking, alcohol abuse and more recently HPV. The TNM system is therefore inadequate to capture the patient-specific biomolecular characteristics of the tumor. HNC treatments can have hard impact on patient’s aesthetics and functionalities and, due to their toxicity, can cause severe morbidity and greatly deteriorate patient’s quality of life. A more precise prognostic prediction than the current TNM system is needed that allows implementing the first-line treatment that maximizes the therapeutic result and minimizes the impacts of therapy.
BD2Decide DSS provides clinicians with the ""means"" and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. BD2Decide realizes and validates an Integrated Decision Support System that links population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multiscale prognostic models. Advanced graphical visualization tools are developed for prognostic data disclosure and patient co-participation to the selected treatment. BD2Decide will improve the clinical decision process, uncover new patient-specific patterns that can improve care, and create a virtuous circle of learning. A multicentric clinical study with more than 1.000 patients will be used to validate the system.
"
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA

Address

Via Gramsci 14
43100 Parma

Italy

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 464 375

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

STICHTING VU

Netherlands

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

Germany

EU Contribution

€ 338 750

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 815 000

UNIVERSIDAD POLITECNICA DE MADRID

Spain

EU Contribution

€ 415 000

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 321 375

ATHENS TECHNOLOGY CENTER ANONYMI BIOMICHANIKI EMPORIKI KAI TECHNIKI ETAIREIA EFARMOGON YPSILIS TECHNOLOGIAS

Greece

EU Contribution

€ 342 000

ALL-IN-IMAGE LTD

Israel

EU Contribution

€ 495 750

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

Netherlands

EU Contribution

€ 373 062,50

POLITECNICO DI MILANO

Italy

EU Contribution

€ 308 750

MULTIMED ENGINEERS SRL

Italy

EU Contribution

€ 150 000

UNIVERSITA DEGLI STUDI DI PARMA

Italy

EU Contribution

€ 60 000

STICHTING VUMC

Netherlands

EU Contribution

€ 760 937,50

Project information

Grant agreement ID: 689715

Status

Closed project

  • Start date

    1 January 2016

  • End date

    30 September 2019

Funded under:

H2020-EU.3.1.5.

  • Overall budget:

    € 4 845 000

  • EU contribution

    € 4 845 000

Coordinated by:

AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA

Italy